Drugs / Temanogrel
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02419820 | Mar 2015 → Apr 2016 | acute coronary syndrome | IlDong Pharmaceutical Co Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT02034292 | Feb → Mar 2014 | acute coronary syndrome | IlDong Pharmaceutical Co Ltd | Terminated | No outcome recorded |
| Phase 1 | NCT00619931 | Jan → Jun 2008 | — | Arena Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00529646 | Jul 2007 → ? | — | Arena Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04915950 | Nov 2021 → Sep 2022 | systemic sclerosis | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT04848220 | May 2021 → Aug 2022 | coronary microvascular disorder | Pfizer | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Temanogrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04915950 ↗ |
| Known as | APD-791 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084617 ↗ |
| Known as | APD791 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02419820 ↗ |
| Known as | Temanogrel hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084617 ↗ |
| Known as | TEMANOGREL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084617 ↗ |
| Modality | Small molecule | — CHEMBL1084617 ↗ |
| Route | Oral | “administered as a single oral dose” NCT00529646 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor inverse agonist” CHEMBL1084617 ↗ |